Nath Bio-Genes (India) Profile
Key Indicators
- Authorised Capital ₹ 21.00 Cr
- Paid Up Capital ₹ 19.00 Cr
- Company Age 31 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 105.40 Cr
- Satisfied Charges ₹ 183.20 Cr
- Revenue Growth 7.72%
- Profit Growth 152.22%
- Ebitda 31.30%
- Net Worth 5.79%
- Total Assets 6.88%
About Nath Bio-Genes (India)
Nath Bio-Genes (India) Limited (NBIL) is a leading Public Limited Indian Non-Government Company incorporated in India on 14 July 1993 and has a history of 31 years and six months. Its registered office is in Aurangabad, Maharashtra, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 537291 and on the National Stock Exchange(NSE) under NATHBIOGEN.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 21.00 Cr and a paid-up capital of Rs 19.00 Cr.
The company currently has active open charges totaling ₹105.40 Cr. The company has closed loans amounting to ₹183.20 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Nath Bio-Genes (India) Limited India are Devinder Khurana as CFO and Dhiraj Rathi as Company Secretary. Satish Kagliwal, Ashu Jain, Akash Kagliwal, and Four other members serve as directors at the Company.
Company Details
-
Location
Aurangabad, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
L01110MH1993PLC072842
-
Company No.
072842
-
Stock Symbol
BSE : 537291 NSE : NATHBIOGEN
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
14 Jul 1993
-
Date of AGM
11 Jul 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Listed
-
ROC Code
Roc Mumbai
Industry
What products or services does Nath Bio-Genes (India) Limited offer?
Nath Bio-Genes (India) Limited offers a wide range of products and services, including Seeds and Plant Saplings, Vegetable Seeds.
Who are the key members and board of directors at Nath Bio-Genes (India)?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satish Kagliwal
|
Managing Director | 29-Mar-2000 | Current |
|
Devinder Khurana
|
CFO | 30-May-2015 | Current |
|
Dhiraj Rathi
|
Company Secretary | 31-Jul-2018 | Current |
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Ashu Jain
|
Director | 01-Oct-2020 | Current |
|
Akash Kagliwal
|
Director | 30-Mar-2007 | Current |
|
Jeevanlata Kagliwal
|
Director | 30-May-2019 | Current |
|
Hitesh Purohit
|
Director | 10-Oct-2012 | Current |
|
Madhukar Deshpande
|
Director | 10-Feb-2021 | Current |
|
Vadla Nagabhushanam
|
Director | 07-Nov-2020 | Current |
Financial Performance of Nath Bio-Genes (India).
Nath Bio-Genes (India) Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.72% increase. The company also saw a substantial improvement in profitability, with a 152.22% increase in profit. The company's net worth moved up by a moderate rise of 5.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nath Bio-Genes (India)?
In 2023, Nath Bio-Genes (India) had a promoter holding of 45.59% and a public holding of 54.40%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Paithan Mega Food Park Private LimitedSatish Kagliwal and Akash Kagliwal are mutual person
-
Nath Industries LimitedAkash Kagliwal, Hitesh Purohit and 1 more are mutual person
-
Agri-Tech (India) LimitedSatish Kagliwal, Jeevanlata Kagliwal and 3 more are mutual person
-
Techindia Nirman LimitedSatish Kagliwal, Jeevanlata Kagliwal and 3 more are mutual person
-
Nath Bio-Technologies LimitedSatish Kagliwal and Jeevanlata Kagliwal are mutual person
-
Nath Holdings And Investments Pvt Ltd
Jeevanlata Kagliwal is a mutual person
Charges (Loans)
₹105.40 Cr
₹183.20 Cr
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 105.30 Cr
- Hdfc Bank Limited : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Nov 2023 | Axis Bank Limited | ₹2.96 M | Open |
| 02 Feb 2023 | Hdfc Bank Limited | ₹1.00 M | Open |
| 29 Jan 2016 | Axis Bank Limited | ₹105.00 Cr | Open |
| 09 Sep 2021 | Axis Bank Limited | ₹18.70 Cr | Satisfied |
| 23 Sep 2020 | Axis Bank Limited | ₹5.00 Cr | Satisfied |
How Many Employees Work at Nath Bio-Genes (India)?
Nath Bio-Genes (India) has a workforce of 417 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nath Bio-Genes (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nath Bio-Genes (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
